Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Financing Activities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Cash from Financing Activities for 11 consecutive years, with $312.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 38.66% year-over-year to $312.8 million, compared with a TTM value of $309.0 million through Dec 2025, down 24.79%, and an annual FY2025 reading of $309.0 million, down 24.79% over the prior year.
  • Cash from Financing Activities was $312.8 million for Q4 2025 at Spyre Therapeutics, up from -$4.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $312.8 million in Q4 2025 and bottomed at -$12.5 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $56.3 million, with a median of $361000.0 recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 2045175.0% in 2023, while the deepest fall reached 9539.23% in 2023.
  • Year by year, Cash from Financing Activities stood at $80000.0 in 2021, then tumbled by 110.0% to -$8000.0 in 2022, then surged by 2045175.0% to $163.6 million in 2023, then skyrocketed by 37.89% to $225.6 million in 2024, then soared by 38.66% to $312.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SYRE at $312.8 million in Q4 2025, -$4.6 million in Q3 2025, and $731000.0 in Q2 2025.